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 Primary open angle glaucoma (POAG) is a complex het-
erogeneous disease and by the year 2020 is predicted to affect
more than 50 million people worldwide [1]. Excavation of the
optic disc with corresponding loss of visual field is the princi-
pal hallmark of POAG. Since its implication in the pathogen-
esis of POAG in 1997, numerous mutations in the myocilin
(MYOC) gene have been identified and their specific pheno-
types characterized [2,3]. The work recently performed by
Shepard and colleagues has revealed that disease severity in
MYOC-related POAG is influenced by exposure of a cryptic
signaling site [4].
Worldwide, the Thr377Met MYOC mutation is one of the
most commonly identified POAG-causing mutations and it
has been previously identified in populations from five differ-
ent continents. This specific mutation has been identified in
four Australian-based families, two families residing in the
United States of America, and one each from Greece, the
former Yugoslavian Republic of Macedonia (FYROM), In-
dia, Finland, and Morocco [5-12]. The Thr377Met MYOC
mutation is located within the COOH-terminal coding region
and renders the protein insoluble [13]. Although this highly
penetrant mutation appears to be sufficient to cause disease,
evidence supporting gene-gene interaction in adult onset glau-
coma has been described in a family harboring this variant
[11]. Members of a Greek family who carried both the
Thr377Met MYOC mutation and a haplotype associated with
the GLC1C locus displayed greater disease severity than did
those family members with only one disease variant [11].
In general, the Thr377Met mutation confers disease of
intermediate severity, with patients typically being diagnosed
in their fourth decade (weighted mean of age at diagnosis across
described pedigrees=41.4 years). This is younger than the age
at which patients with the Gln368Stop mutation are usually
diagnosed, yet somewhat older than those carrying other
MYOC mutations such as Pro370Leu, which is generally di-
agnosed around 15 years of age [5-12]. Following a similar
pattern, patients with the Thr377Met mutation tend to have a
maximum recorded intraocular pressure around 30 mmHg,
lower than that described for mutations causing juvenile on-
set glaucoma (such as Pro370Leu), though generally higher
than for the Gln368Stop mutation [7].
Inherited diseases with a relatively late onset may be more
likely to have a common disease founder than those which
manifest at a younger age. Evidence for a founding effect has
previously been reported for the common Gln368Stop MYOC
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487mutation; however, others, such as the Gly367Arg mutation,
have arisen independently several times [14-16]. Small, local
founder effects have also been identified for other less com-
mon mutations [9,14,17-19]. It is unclear whether a POAG
variant causing intermediate disease severity would dissemi-
nate worldwide. Herein, we identified the haplotypes associ-
ated with the Thr377Met MYOC mutation to evaluate a pos-
sible founder effect in POAG families from various different
ethnic backgrounds. To assess the degree of linkage disequi-
librium across MYOC in the general population we also in-
vestigated data generated from the HapMap consortium.
METHODS
 Nine Thr377Met MYOC glaucoma pedigrees from the United
States of America, Greece, Finland, India, and Australia were
recruited. The four Australian families had emigrated from
Great Britain, Greece, and Macedonia. Both families from the
United States of America were of Greek ethnicity (Table 1).
The Indian proband lived in a Sino-Tibetan linguistic region.
This study adhered to the Declaration of Helsinki and ethical
approval had previously been obtained by each research
group’s respective local Institutional Review Board, as previ-
ously reported [5-12].
Six microsatellite markers (D1S2851, MY3, My5,
D1S1619, D1S2790, and D1S242) and four single nucleotide
polymorphisms (rs3768570, rs235858, rs171000, and
rs235873) located within a four Mb region surrounding the
MYOC gene were genotyped in available subjects from each
pedigree. Primer sequence and PCR conditions are available
upon request. Haplotypes in each family were constructed by
visual inspection of the genotype data, with no recombina-
tions assumed between the markers. Genomic DNA was avail-
©2007 Molecular Vision Molecular Vision 2007; 13:487-92 <http://www.molvis.org/molvis/v13/a51/>
TABLE 1. SUMMARY OF PHENOTYPIC FEATURES OF GLAUCOMATOUS INDIVIDUALS CARRYING THE THR377MET MYOC MUTATION
In the table, abbreviations are: n, number; SE, standard error; POAG, primary open angle glaucoma; OHT, ocular hypertension; IOP, intraocu-
lar pressure; USA, United States of America.
TABLE 2. ANCESTRAL DISEASE HAPLOTYPE SHARED BY INDIVIDUALS CARRYING THE THR377MET MYOC MUTATION FROM DIFFERENT ETHNIC
BACKGROUNDS
488able from only one individual from the Indian cohort.
To estimate the probability of finding non-coincidental
haplotypes segregating with the founded Thr377Met MYOC
mutation, we determined the frequencies of the associated
neighboring alleles in a sample of POAG patients originating
from the same ethnic background. Thirty-three genealogically
unrelated POAG patients of Greek ethnicity who, on direct
sequencing, were found not to have the Thr377Met MYOC
mutation, were recruited. The frequencies of the founded hap-
lotype between the Greek Thr377Met MYOC mutation carry-
ing patients and the Greek non-MYOC POAG patients was
compared using Fisher’s exact test (Intercooled Stata 7.0 for
Windows; Stata Corporation, College Station, TX).
Allele frequencies and linkage disequilibrium across the
chromosome region 1q24 was assessed using HapMap data
[20]. Phase I and II data were accessed from public release
21. This data release contains all processed data from the
project including genotypes from the Affymetric 500 k
genotyping array. HapMap comprises data of genotyped indi-
viduals from the Centre d’Etude du Polymorphisme Humain
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Figure 1. Haplotype blocks of the 320 kbp region containing the myocilin (MYOC) gene, in subjects from the Centre d’Etude du Polymorphisme
Humain collection in Utah.  The plotted D’ statistic is orientated to the MYOC ideogram position and the strength of linkage disequilibrium is
displayed in increasing shades of red for higher values. The relative gene locations are indicated by yellow bars.
489collection in Utah; the Yoruba in Ibadan, Nigeria; the Han
Chinese in Beijing, China; and the Japanese in Tokyo, Japan
[20]. Haplotype blocks were reviewed using Haploview 3.32
[21] and defined as having an upper confidence interval maxi-
mum for strong recombination of 0.9 [22]. Markers with a
minor allele frequency below 0.05 were excluded [22].
RESULTS
 Genotyping of the microsatellite markers revealed a shared
haplotype in mutation carriers across six families from Greece,
the United States of America, and Australia (Table 2). All of
these families were known to be of Greek or Macedonian
ethnicity and recombination was found to have occurred in a
region telomeric to MYOC between D1S1619 and D1S2790.
To investigate whether the haplotype observed in the
Greek/FYROM Thr377Met MYOC families was inherited only
by chance we genotyped a small cohort of POAG patients of
Greek ethnicity who were known not to have the Thr377Met
MYOC mutation. Although the precise phase could not be fully
determined because of the limited availability of other family
members, one Greek patient with POAG was found to have
markers (between My3 and D1S1619) in common with the
founded Greek Thr377Met MYOC mutation. However, even
with the conservative assumption that this patient did have
the founded MYOC haplotype, our data supports the rejection
of the hypothesis that the Greek Thr377Met haplotype merely
represents frequent alleles (p<0.0001).
The families from Finland and Great Britain were found
to have differing haplotypes from each other and from those
which originated from Greece or Macedonia. This suggests
that the Thr377Met MYOC mutation has arisen at least three
times worldwide. The Indian proband was found to have some
markers in common both with the Finnish pedigree and the
family which originated from Great Britain. However, given
that only one case from this family could be ascertained, the
haplotype segregating with the Thr377Met MYOC mutation
could not be fully determined.
Reviewing the data generated by the HapMap consortium
revealed that linkage disequilibrium across MYOC, particu-
larly in the Utah residents, was not strong (Figure 1). Larger
linkage disequilibrium blocks over the genes neighboring
MYOC (HbxAg transactivated protein 2 and vesicle-associ-
ated membrane protein 4) were identified. In each population
linkage disequilibrium was generally stronger across exons 2
and 3 compared to the 5' region of the MYOC gene.
DISCUSSION
 Pre-symptomatic screening for glaucoma is an attractive pros-
pect and although it may be currently uneconomical to intro-
duce MYOC gene screening in a population-wide approach,
targeted screening is warranted in selected populations. Our
results imply that the Thr377Met MYOC mutation should be
considered in glaucoma patients of Greek descent in particu-
lar.
A common haplotype was identified with the Thr377Met
MYOC in six of the nine genealogically independent pedigrees
studied. The northern boundary of Epirus, Greece, where the
Ep1 family in this report lives, forms the southern edge of the
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Figure 2. The worldwide spread of the Thr377Met MYOC mutation.  Stars indicate location of known origin, solid arrows indicate known
migrations, and the dashed arrow indicates an inferred migration.
490FYROM. Given this geographical proximity, we surmised that
the Australian families from Greece and the FYROM have a
common founder. However, the British, Finnish, and Indian
families have a distinct haplotype from the Greek one, sug-
gesting that the Thr377Met mutation has occurred de novo
more than once (Figure 2). Unfortunately refinement of the
haplotype associated with this mutation in the Indian case was
limited by the lack of genetically informative relatives. None-
theless, we hypothesize that a Finnish-Indian connection would
be at least 1,500 years old, from when the Finno-Ugric (Huns)
people migrated from Central Asia. To investigate this inferred
dissemination further it would be imperative to collect addi-
tional samples from the Indian Thr377Met MYOC family, as
well as other unrelated Indian POAG cases. A limitation of
our work is that the location of the centromeric and telomeric
recombination in each pedigree was not identified. Such in-
formation would allow for the identification of the minimal
common genomic distance between mutation carriers and, in
turn, provide an estimation of the age at which the Thr377Met
mutation occurred, yet is beyond the scope of this work [23,24].
The population spread of human disease is significantly
influenced by relative selection pressures and the existence of
founder effects raises questions about whether such pressures
are playing a role in MYOC allele frequencies. Our results,
coupled with the late age at diagnosis (with the weighted mean
across published pedigrees being 41.4 years), suggest that the
Thr377Met MYOC mutation alone may not be significantly
detrimental to reproduction. Although it is possible to arrive
at a founder effect through non-selective processes such as
genetic drift, it is plausible that this glaucoma-causing muta-
tion may act as a protective factor against a separate ailment,
thereby positively affecting biological fitness. Further insights
may come from studies of Thr377Met allele frequencies in
the Greek glaucoma populations. Evidence for genetic founder
effects in this prevalent age-related, yet heterogeneous, dis-
ease has important implications for future gene identification
strategies.
The haplotype structure across the comparatively small
region surrounding MYOC, in conjunction with relatively small
proportion of disease accounted for by mutations in MYOC,
suggests that a high density SNP platform would be required
for it to have been identified using a genome-wide association
case-control approach. Nevertheless, genes with a different
allelic architecture could be identified using such technology
and, interestingly, a common disease haplotype has recently
been associated with the common Y402H variant of Comple-
ment Factor H implicated in age-related macular degenera-
tion [25]. Although confined conclusions based on the HapMap
data must be approached with caution and the populations from
which the data were generated should not be over-general-
ized, we found that linkage disequilibrium was marginally
stronger across the regions with greater cross-species homol-
ogy (particularly exon 3). Interestingly this supports other find-
ings that on a genome-wide level sequence conservation ap-
pears not to be an important predictor of linkage disequilib-
rium [26].
In summary, the Thr377Met MYOC mutation has arisen
at least three times in independent populations. Interestingly
however, HapMap data suggest that linkage disequilibrium
across MYOC is not strong. Evidence for genetic founder ef-
fects in this prevalent age-related, yet heterogeneous disease
has important implications for future gene identification strat-
egies.
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